Comparing Altimmune (NASDAQ:ALT) and Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) and Altimmune (NASDAQ:ALT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Earnings and Valuation

This table compares Insmed and Altimmune”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42 million	35.92	-$1.28 billion	($4.11)	-24.27
Altimmune	$31,000.00	14,714.35	-$88.09 million	($0.78)	-3.01

Altimmune has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Insmed has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Insmed and Altimmune, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1	1	22	1	2.92
Altimmune	1	1	8	0	2.70

Insmed presently has a consensus price target of $200.30, suggesting a potential upside of 100.84%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 511.23%. Given Altimmune’s higher probable upside, analysts clearly believe Altimmune is more favorable than Insmed.

Insider and Institutional Ownership

78.1% of Altimmune shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Insmed and Altimmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Altimmune	N/A	-31.41%	-26.96%

Summary

Altimmune beats Insmed on 9 of the 15 factors compared between the two stocks.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.